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Breast cancer is predominantly a disease of older women, yet there is a knowledge gap due to the
persisting misalignment between the age distribution of women with breast cancer and the age
distribution of participants in clinical trials. The purpose of this report is to state the U13
conference breast cancer panel’s recommendations regarding therapeutic clinical trials that will fill
gaps in knowledge regarding the care of older patients with breast cancer. The U13 conference
was a collaboration between the Cancer and Aging Research Group and the National Institute on
Aging and the National Cancer Institute (NCI). Clinical trials should be developed for frail and
vulnerable patients who would not enroll on the standard phase III trials, as well as efforts need to
be made to increase enrollment of fit older patients on standard phase III trials. As a result of this
conference, panel members are working with the NCI and cooperative groups to address these
knowledge gaps. With the aging population and increasing incidence of breast cancer with age, it
is essential to study the feasibility, toxicity, and efficacy of cancer therapy in this at-risk
population.
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In the USA, over 200,000 women are diagnosed with breast cancer each year [1]. Breast
cancer incidence and mortality rates increase with age and nearly one half of all new breast
cancer diagnoses occur in women age 65 and older [2]. By 2030, it is estimated that 20 % of
the population in the USA will be older than 65 years of age resulting in an exponential
growth of older women with breast cancer [3]. National treatment guidelines do not set an
upper age limit for the use of chemotherapy, but acknowledge that comorbid medical
conditions and life expectancy must be considered when prescribing chemotherapy [4].
However, many comorbid medical conditions in older patients are well controlled and
treated [5, 6]. Subsequently, the average life expectancy is increasing, and as a result, the
risk of breast cancer relapse during the remaining lifespan becomes an important
consideration. On average, 65- and 75-year-old patients have an anticipated life expectancy
of 20 and 12 years, respectively [7]. Furthermore, the number and proportion of people at
very old ages is increasing (Fig. 1).
Chemotherapy has been shown to improve breast cancer-related health outcomes, including
survival, in women with breast cancer [8]. Women aged 50–65 years with early stage breast
cancer will achieve a 20 % proportional reduction in the risk of recurrence and an 11 %
proportional reduction in the risk of death with adjuvant chemotherapy [8]. Furthermore, a
recent clinical trial in women with estrogen receptor-positive breast cancer reported that
breast cancer-specific mortality was 25 % higher for women between the ages of 65 and 74
(HR 1.25; 95 % CI 1.01–1.54), and 63 % higher for women 75 years of age or older (HR
1.63; 95 % CI 1.23–2.16), compared with women under the age of 65 (p < 0.001) [9]. The
investigators speculated the significant increase in breast cancer-specific mortality in older
women was potentially secondary to difference in age-related treatment patterns, with older
adults less likely to receive standard treatments. In particular, only 5.2 % of patients aged 75
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and over received adjuvant chemotherapy despite 48 % of these patients having node
positive disease.
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The lack of clinical trial data in older women with breast cancer and the growing number of
older women with breast cancer are a significant challenge to medical oncologists, not only
because of the increasing numbers, but also because of physiologic changes due to aging,
which may increase the risk of treatment toxicity and compromise the ability to deliver
therapy [10]. To compound this problem, less evidence-based data are available to guide the
care of the growing number of older women with breast cancer as older patients are
disproportionately underrepresented in breast cancer clinical trials [11]. To bridge this
knowledge gap, a U13 conference grant (U13 AG038151), “Geriatric Oncology Research to
Improve Clinical Care,” a cooperative conference grant between the Cancer and Aging
Research Group in collaboration with the Geriatrics and Clinical Gerontology branch of the
National Institute on Aging (NIA) and the National Cancer Institute (NCI) was formed.
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The U13 conference, “Design and Implementation of Therapeutic Clinical Trials for Older
and/or Frail Adults with Cancer,” brought together multidisciplinary investigators from
geriatrics and oncology to identify and address the areas of highest research priorities in
cancer and aging and therapeutic clinical trials for older and/or frail adults with cancer.
Here, we report the U13 conference breast cancer panel’s recommendations regarding
therapeutic clinical trials that will fill gaps in knowledge regarding the care of older patients
with breast cancer.
Breast cancer and aging: treatment in the adjuvant setting
Age is no longer a valid eligibility criterion in and of itself, and the majority of the NCI’s
clinical trial cooperative groups no longer specify an upper age limit. Data suggest that older
patients who enroll in clinical trials tolerate the standard chemotherapy regimens, and even
intensive regimens, although older adults are at increased risk for treatment toxicity [12, 13].
In addition, data demonstrate a significant survival benefit for standard chemotherapy
regimens in healthy older patients that meet stringent eligibility criteria for these trials [13].
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Age bias plays a major role in offering clinical trials to patients, even in major cooperative
group institutions [11]. In a review of patient accrual to three breast cancer adjuvant
chemotherapy trials in the Cancer and Leukemia Group B (CALGB), none of which had an
upper age limit that excluded older women, only 8 % of patients were older than 65 years,
and only 4 % were older than age 70 [11]. Interestingly, data support similar willingness to
enroll in clinical trials when research studies are offered to both older and younger patients;
however, older adults were less likely to be offered clinical trial participation [11]. While
data have shown that standard chemotherapy regimens improve treatment outcomes in older
patients with breast cancer, the potential for increased chemotherapy-related toxic effects is
an important concern. For example, renal function and bone marrow reserve decrease with
age and can increase the risk of toxic effects from treatment regimens that include
myelosuppressive agents or agents that are renally excreted [14]. Hence, there is a need to
identify the frail older individual who is apt to experience undue side effects and requires a
modified treatment plan as well as the fit older individual likely to benefit from and tolerate
standard therapy.
Breast Cancer Res Treat. Author manuscript; available in PMC 2015 July 01.
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To fill this need and bridge the knowledge gap of the toxicity and feasibility of established
adjuvant therapies in older breast cancer patients, the U13 breast cancer panel recommended
designing therapeutic clinical trials of established adjuvant chemotherapy regimens for older
women with breast cancer. These studies would incorporate a comprehensive geriatric
assessment in order to identify the factors other than age for increased risk of toxicity from
therapy, in order to guide future interventions to decrease this risk. A geriatric assessment
evaluates functional status, comorbidity, cognition, psychologic state, social support, and
nutritional status, which are independent predictors of the risk of morbidity/mortality in
older adults (Fig. 3) [15, 16].
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An example of this approach would be studying dose-dense therapy, as described in the
Intergroup Trial C9741, which has been widely adopted in the USA for the adjuvant
treatment of patients with node positive breast cancer [17]. This prospective clinical trial had
4 arms and tested two hypotheses (Fig. 2). The first hypothesis was that the efficacy of
adjuvant chemotherapy may be improved with sequential drug administration, not
combination drug administration. The second hypothesis was that the efficacy of adjuvant
chemotherapy may be improved by increasing the dose density of the regimen by delivering
standard-dose chemotherapy with shorter intervals (2 rather than 3 weeks) between
treatment cycles. At a median follow-up of 36 months, dose-dense treatment improved the
primary end points, disease-free survival (DFS) [risk ratio (RR) = 0.74; p = 0.010], and
overall survival (OS) [RR 0.69; p = 0.013]. There was no difference in either DFS or OS
between the concurrent and sequential treatment schedules. Subsequently, dose-dense
adjuvant chemotherapy has become an internationally recognized option for patients with
high-risk breast cancer (Fig. 3).
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The fact that sequential versus combination therapy yields comparable outcomes provides a
scientific basis for studying the efficacy of other therapies sequentially in a potentially
curative manner. Furthermore, the dose and number of chemotherapy drugs used are risk
factors for older adults with cancer in developing grade 3–5 toxicities [18]. Therefore,
sequential therapy may be better tolerated in the older patients, allowing the ability to
deliver optimal dose intensity. Unfortunately, only two percent of patients enrolled in
Intergroup Trial C9741 were aged 70 or older, and geriatric assessments were not
performed. Therefore, the U13 conference breast cancer panel proposes a dose-dense
sequential chemotherapy as used in C9741 for older patients with breast cancer who are at a
high risk of recurrence to evaluate the feasibility of completing this adjuvant chemotherapy
regimen, as well as to identify the risk factors for toxicity. This study may be particularly
useful in a frail or vulnerable population who is deemed to be at high risk of side effects
from combination chemotherapy. Incorporation of a geriatric assessment pretreatment would
be utilized to understand factors other than (or in addition to) chronological age, which place
patients at increased risk for treatment toxicity. Incorporation of geriatric assessment in
longitudinal follow-up would be utilized to identify which patients are at risk for short- or
long-term declines in physical function, as well as to evaluate the impact of treatment
toxicity on these parameters.
With solid evidence showing that older women receiving anthracycline-based adjuvant
chemotherapy have higher rates of congestive heart failure after completing treatment, a
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second recommendation for a therapeutic adjuvant clinical trial for older patients with breast
cancer is to evaluate a nonanthracycline chemotherapy regimen in patients with a high risk
of breast cancer recurrence, utilizing the same framework as described above [19]. As well
as confirming breast cancer outcomes with an established nonanthracycline chemotherapy
regimen, investigators are encouraged to incorporate a geriatric assessment to evaluate
factors other than or in addition to age that might identify those individuals who are most
likely to tolerate the cytotoxic regimen or which patient need additional support.
These suggested research studies are examples of designing therapeutic clinical trials
integrating geriatric and oncology principles. These studies could fill critical gaps in the
knowledge of adjuvant chemotherapy feasibility, tolerability, and toxicity in older patients
with breast cancer.
Breast cancer and aging: treatment in metastatic setting
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Despite the compelling demographics of cancer and aging and the recommendations of
expert societies, the enrollment of older adults in registration trials remains dismal. (REF)
Since 2007, six drugs have been approved by the US food and Drug Administration for the
treatment of breast cancer (Table 1). According to the geriatric usage sections of the drug
package inserts, on average, only 20 % of patients included in the registration trials were
aged 65 years or older and 4 % of patients included were aged 75 years or older. As
approximately half of all breast cancer diagnoses occur in women over the age of 60, the
patients enrolled in the registration trials are likely not representative of the patient
population where these agents will be prescribed.
Ixabepilone in combination with capecitabine was granted FDA approval based on a
statistically significant improvement in median progression-free survival of 5.7 versus 4.1
months (HR 0.69; 95 % CI, 0.58–0.83; p < 0.001) with the combination of ixabepilone plus
capecitabine compared with capecitabine monotherapy, in the treatment of patients with
metastatic breast cancer who progress after an anthracycline and taxane [20]. Ten percent of
the enrolled patients were aged 65 and older and <1 % of patients enrolled were aged 75 and
older. The overall incidence of grade 3 and 4 adverse events were significantly higher in
patients over age 65, compared with patients under age 65 (82 vs. 68 %) including grade 3
and 4 stomatitis (9 vs. 1 %), febrile neutropenia (9 vs. 3 %), and fatigue (16 vs. 12 %) [20].
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In the randomized study of patients with advanced hormone receptor-positive, HER2negative breast cancer study, treated with exemestane ± everolimus, the incidence of deaths
due to any cause within 28 days of the last everolimus dose was 6 % in patients over 65
years of age compared with 2 % in patients under 65 years of age [21]. Adverse reactions
leading to permanent treatment discontinuation occurred in 33 % of patients over 65 years of
age compared with 17 % in patients under 65 years of age.
The U13 breast cancer panel recommended performing a series of phase II studies in
recently FDA approved drugs in older women with metastatic breast cancer. These studies
should incorporate a geriatric assessment to identify predictors of toxicity based on geriatric
variables and evaluate tolerability (toxicity and feasibility). If there is a concern regarding
the potential toxicity of the therapy in older adults, then clinical trial schemes can be
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modified to build in additional safety criteria. For example, the study could include an initial
dose reductions followed by dose escalations to standard doses in older patients that tolerate
therapy. This approach would be favored in patients in metastatic disease where a key goal
was palliation and maintenance of quality of life. It would not be recommended in the
adjuvant setting where decreased dose intensity could impact the curative intent of the
regimen.
The biggest challenge to fill the knowledge gaps on treatment of metastatic breast cancer is
to get an adequate representation of older adults on clinical trials. One way of accomplishing
this is to prespecify the inclusion of a specific proportion of older patients (which mirrors
the percentage of individuals within the age group with the disease) in the study design.
Alternatively, if there is concern that this would slow the accrual to clinical trials, then the
study could be expanded postcompletion to obtain an adequate number of older adults in
order to fill the gap in knowledge regarding the efficacy and toxicity of the treatment in this
patient population.

Conclusion
NIH-PA Author Manuscript

Breast cancer is predominantly a disease of older women, yet there is a knowledge gap due
to the persisting misalignment between the age distribution of women with breast cancer and
the age distribution of participants in clinical trials. To address these gaps, future clinical
research for older patients with breast cancer should include a geriatric assessment that can
be utilized to identify individuals who may be at risk for treatment-related side effects,
which require a modified treatment plan. Trials should be developed for frail and vulnerable
patients who would not enroll on the standard phase III trials, as well as efforts need to be
made to increase enrollment of fit older patients on standard phase III trials. Ultimately,
enhanced research collaborations between oncologists, geriatricians, and a multidisciplinary
team are needed to address issues pertinent to older patients. As a result of this conference,
panel members are working with the NCI and cooperative groups to address these
knowledge gaps.
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Percentage Change in the World’s Population by Age: 2010–2050. United Nations, World
Population Prospects: The 2010 Revision. Available at: http://esa.un.org/unpd/wpp
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Fig. 2.

The treatment arms of the Intergroup Trial C9741/cancer and leukemia group B Trial 974117
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Fig. 3.

Recommendations to bridge the knowledge gap in older women with breast cancer in the
adjuvant setting
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FDA approved agents in breast cancer since 2007
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Agents

Date
approved

Indication

Age

Ixabepilone [22]

10/2007

Combination with capecitabine in metastatic or locally advanced
breast cancer resistant to treatment with an anthracycline and a
taxane

10

<1

10/2007

Monotherapy in metastatic or locally advanced breast cancer resistant
to anthracyclines, taxanes, and capecitabine

13

3

Eribulin [23]

11/2010

Third-line treatment metastatic breast cancer

15

2

Everolimus [21]

7/2012

Advanced hormone receptor-positive, HER2-negative breast cancer in
combination with exemestane, after failure of treatment with
letrozole or anastrozole

40

15

Ado-trastuzumab
emtansine [24]

2/2013

HER2-positive breast cancer following treatment with trastuzumab
and a taxane

13

2

Pertuzumab [25]

6/2012

Combination with trastuzumab and docetaxel in HER2-positive
metastatic breast cancer who have not received prior anti-HER2
therapy

15

1

Lapatinib [26, 27]

1/2010

Combination with capecitabine in metastatic HER2-positive breast
cancer

17

1

Combination with letrozole in metastatic HER2-positive breast cancer

44

12

>65 (%)

>75 (%)

You should organize the agents alphabetically or by the date of approval
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